Comparative study of Ulipristal and Ormeloxifene in treatment of uterine fibroids

Abstract

This study was conducted among reproductive age women between 30-50 yrs diagnosed with uterine fibroids to compare the efficacy and safety of Ormeloxifene and Ulipristal in treatment of uterine fibroids. Methodology: Prospective interventional study was conducted from May 2021 to September 2022 among 40 patients diagnosed with uterine fibroids who were randomly divided into two groups, 20 patients in each group, Group 1 were given Ormeloxifene and group 2 were given Ulipristal Results: Mean fibroids size reduced in patients who took Ulipristal than in Ormeloxifene group which was statistically significant. Mean HB CONC increased in Ulipristal group than in Ormeloxifene group which was statistically insignificant. Conclusion:Ulipristal is better as compared to ormeloxifene in reduction of fibroid size. Ulipristal also reduced menstrual blood loss and improved hemoglobin levels when compared to Ormeloxifene.